EGFR and neoplasm: The tumor bearing animals (n = 6) first received 3 doses of wt-p53 plasmid (20 μg plasmid/dose) encapsulated in thiolated, non-targeted and EGFR-targeted thiolated gelatin nanoparticles at day 0, 2 and 4.